• Explore /
  • Poster
  • / Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.

Abstract Poster

Authors

Manish Shah

Manish A. Shah

Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY

Manish A. Shah , Antoine Adenis , Peter C. Enzinger , Takashi Kojima , Kei Muro , Jaafar Bennouna , Eric FRANCOIS , Chih-Hung Hsu , Toshikazu Moriwaki , Sung-Bae Kim , Se-Hoon Lee , Ken Kato , Lin Shen , Shukui Qin , Paula Ferreira , Ruixue Wang , Pooja Bhagia , S. Peter Kang , Jean-Philippe Metges , Toshihiko Doi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT02564263

Citation

J Clin Oncol 37, 2019 (suppl; abstr 4010)

DOI

10.1200/JCO.2019.37.15_suppl.4010

Abstract #

4010

Poster Bd #

115

Abstract Disclosures

Similar Posters

First Author: Zev A. Wainberg

First Author: Kuaile Zhao

First Author: Joaquim Bellmunt

First Author: Lin Shen